161 related articles for article (PubMed ID: 30549062)
41. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.
Liu M; Li C; Pazgier M; Li C; Mao Y; Lv Y; Gu B; Wei G; Yuan W; Zhan C; Lu WY; Lu W
Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14321-6. PubMed ID: 20660730
[TBL] [Abstract][Full Text] [Related]
42. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
[TBL] [Abstract][Full Text] [Related]
43. MDMX acidic domain inhibits p53 DNA binding in vivo and regulates tumorigenesis.
Huang Q; Chen L; Yang L; Xie X; Gan L; Cleveland JL; Chen J
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3368-E3377. PubMed ID: 29581299
[TBL] [Abstract][Full Text] [Related]
44. Comparative study of the p53-mdm2 and p53-MDMX interfaces.
Böttger V; Böttger A; Garcia-Echeverria C; Ramos YF; van der Eb AJ; Jochemsen AG; Lane DP
Oncogene; 1999 Jan; 18(1):189-99. PubMed ID: 9926934
[TBL] [Abstract][Full Text] [Related]
45. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation.
Okamoto K; Kashima K; Pereg Y; Ishida M; Yamazaki S; Nota A; Teunisse A; Migliorini D; Kitabayashi I; Marine JC; Prives C; Shiloh Y; Jochemsen AG; Taya Y
Mol Cell Biol; 2005 Nov; 25(21):9608-20. PubMed ID: 16227609
[TBL] [Abstract][Full Text] [Related]
46. Autoinhibition of MDMX by intramolecular p53 mimicry.
Chen L; Borcherds W; Wu S; Becker A; Schonbrunn E; Daughdrill GW; Chen J
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4624-9. PubMed ID: 25825738
[TBL] [Abstract][Full Text] [Related]
47. Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.
Patil SP; Pacitti MF; Gilroy KS; Ruggiero JC; Griffin JD; Butera JJ; Notarfrancesco JM; Tran S; Stoddart JW
J Comput Aided Mol Des; 2015 Feb; 29(2):155-63. PubMed ID: 25377899
[TBL] [Abstract][Full Text] [Related]
48. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
Okamoto K; Taya Y; Nakagama H
FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
[TBL] [Abstract][Full Text] [Related]
49. Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction.
Thayer KM; Beyer GA
PLoS One; 2016; 11(3):e0147806. PubMed ID: 26992014
[TBL] [Abstract][Full Text] [Related]
50. Predicted functions of MdmX in fine-tuning the response of p53 to DNA damage.
Kim S; Aladjem MI; McFadden GB; Kohn KW
PLoS Comput Biol; 2010 Feb; 6(2):e1000665. PubMed ID: 20174603
[TBL] [Abstract][Full Text] [Related]
51. Rigorous Computational and Experimental Investigations on MDM2/MDMX-Targeted Linear and Macrocyclic Peptides.
Diller DJ; Swanson J; Bayden AS; Brown CJ; Thean D; Lane DP; Partridge AW; Sawyer TK; Audie J
Molecules; 2019 Dec; 24(24):. PubMed ID: 31847417
[TBL] [Abstract][Full Text] [Related]
52. The MDMX Acidic Domain Uses Allovalency to Bind Both p53 and MDMX.
Fenton M; Borcherds W; Chen L; Anbanandam A; Levy R; Chen J; Daughdrill G
J Mol Biol; 2022 Nov; 434(22):167844. PubMed ID: 36181774
[TBL] [Abstract][Full Text] [Related]
53. Casein kinase 1α regulates an MDMX intramolecular interaction to stimulate p53 binding.
Wu S; Chen L; Becker A; Schonbrunn E; Chen J
Mol Cell Biol; 2012 Dec; 32(23):4821-32. PubMed ID: 23028042
[TBL] [Abstract][Full Text] [Related]
54. MDMX inhibits the p300/CBP-mediated acetylation of p53.
Sabbatini P; McCormick F
DNA Cell Biol; 2002 Jul; 21(7):519-25. PubMed ID: 12162806
[TBL] [Abstract][Full Text] [Related]
55. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
Liu Y; Wang X; Wang G; Yang Y; Yuan Y; Ouyang L
Eur J Med Chem; 2019 Aug; 176():92-104. PubMed ID: 31100649
[TBL] [Abstract][Full Text] [Related]
56. MdmX inhibits Smad transactivation.
Kadakia M; Brown TL; McGorry MM; Berberich SJ
Oncogene; 2002 Dec; 21(57):8776-85. PubMed ID: 12483531
[TBL] [Abstract][Full Text] [Related]
57. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
Golestanian S; Sharifi A; Popowicz GM; Azizian H; Foroumadi A; Szwagierczak A; Holak TA; Amanlou M
Life Sci; 2016 Jan; 145():240-6. PubMed ID: 26746660
[TBL] [Abstract][Full Text] [Related]
58. Identification of small molecules affecting p53-MDM2/MDMX interaction by fluorescence polarization.
Zhang Q; Lu H
Methods Mol Biol; 2013; 962():95-111. PubMed ID: 23150440
[TBL] [Abstract][Full Text] [Related]
59. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
60. Group-based QSAR and molecular dynamics mechanistic analysis revealing the mode of action of novel piperidinone derived protein-protein inhibitors of p53-MDM2.
Goyal S; Grover S; Dhanjal JK; Tyagi C; Goyal M; Grover A
J Mol Graph Model; 2014 Jun; 51():64-72. PubMed ID: 24858256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
